Would you like to participate ask a question join the surfers in our next episode?

S2-E21 – Day One At The 4th Global NASH Congress — Diagnostics, Drugs And Regulatory Issues

Manal Abdelmalek, Jörn Schattenberg and GenFit Global Diagnostics Leader Suneil Hosmane join the Surfers to review presentations from Day Two at the 4th Global NASH Congress.

On April 28, over 175 NASH stakeholders from across the globe will meet virtually to hear 23 presentations from leaders in academia and industry. SurfingNASH has selected 11 presentations to discuss in a session we will record right after the conference concludes. The speakers and their broad topic areas are:
Manal Abdelmalek — innovative non-invasive non-device diagnostics
Jörn Schattenberg — Developmental drugs that address fructose metabolism
Suneil Hosmane — Leading edge diagnostic strategies and agents in development
Louise Campbell — Challenges in using and assessing non-invasive diagnostics in initial diagnosis and secondary/tertiary patient care
Roger Green — Regulatory perspectives

TOPICS: 89bio, cirrhosis, Diabetes, Diagnostic Tests, Fatty Liver, FDA, FGF-21, Fibrosis Level 3, Fibrosis Level 4, Genfit, Gilead Sciences, NAFLD, NASH, non-invasive liver testing, Nordic Biosciences, Owlstone Medical, Pfizer, Glympse Bio, Liquid biopsy, EMA, Somalogic, Proteomics, microRNA, Fructose metabolism, BIO89-100,

Surfing The NASH Tsunami is brought to you by HEP Dynamics
#HEPdynamics #SurfingNASH #podcast

Request Transcript of This Episode
Request Transcript

NASH & Diabetes Podcast and NASH Tsunami Podcast